osimertinib

1. 18:42
   ESMO 2026 现场信号

   ☝🏼#ESMO26 Targeted therapies: toxicity is not just about the drug — context matters.
2. 18:06
   ESMO 2026 现场信号

   🧬 Early ctDNA clearance tells us a lot about prognosis — but not necessarily which treatment to choose.
3. 15:49
   ESMO 2026 现场信号

   Temab-A an ADC antiMET good activty in MET+ nonSq pretreted wt and EGFRm NSCLC. But: easy to test biomarker in daily practice? In EGFRm cohort higher activity if we add osimertinib
4. 15:07
   ESMO 2026 现场信号

   Superb discussion by @LeXiuning at #ESMO26 on ctDNA-guided treatment selection in EGFRm NSCLC.
5. 15:06
   ESMO 2026 现场信号

   Interesting integration of ctdna directed therapy in NSCLC
6. 15:00
   ESMO 2026 现场信号

   #FLAURA2: Early ctDNA clearance didn’t identify who could forgo chemotherapy—PFS favored osimertinib + chemo regardless of week 1–2 clearance. Similar clearance rates, different ou
7. 14:49
   ESMO 2026 现场信号

   🚨 ESMO 2026 | FLAURA2 ctDNA Analysis
8. 14:37
   ESMO 2026 现场信号

   #ESMO26 Dr. Martin Sebastian presents PACE-LUNG: phase II study of osimertinib monotherapy for EGFR NSCLC with ctDNA at 3w and if positive, add 4 cycles of chemotherapy. 72/255 wer
9. 13:25
   ESMO 2026 现场信号

   OncoAlert 4Sight Abstracts to be Presented at #ESMO26
10. 03:28
    ESMO 2026 现场信号

    #ESMO2026 opened today in Madrid, and a big focus for EGFR+ #lungcancer is what happens when osimertinib stops working.

1. 00:50
   ESMO 2026 现场信号

   @HHorinouchi's FLAURA2 summary carries the teaching point of the day: early plasma EGFRm clearance was prognostic but not predictive, so it shouldn't be the reason to add or skip c

1. 20:00
   临床试验登记

   Osimertinib 单药或联合 Cyclosporine A 治疗 EGFR 突变非小细胞肺癌的 2 期随机试验启动招募

   NYU Langone Health 启动 2 期随机试验（NCT07874490），在 EGFR 突变非小细胞肺癌患者中评估 osimertinib 联合或不联合 cyclosporine A 的疗效，计划入组 60 例。

当前热度 57·可比范围峰值 90（10月24日 19:00）·近 24 小时可比范围变化 +471%·当前参与者 11

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。